A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Saved in:

Bibliographic Details
Title:	A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Authors:	Alcaraz LB; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., Mallavialle A; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., David T; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., Derocq D; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., Delolme F; University of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.; University of Lyon, ENS de Lyon, INSERM US8, CNRS UMS3444, SFR Biosciences, F-69366 Lyon, France., Dieryckx C; University of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.; University of Lyon, ENS de Lyon, INSERM US8, CNRS UMS3444, SFR Biosciences, F-69366 Lyon, France., Mollevi C; Biometry department, ICM, Montpellier, France., Boissière-Michot F; Translational Research Unit, ICM, Montpellier, France., Simony-Lafontaine J; Translational Research Unit, ICM, Montpellier, France., Du Manoir S; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., Huesgen PF; University of British Columbia, Faculty of Dentistry, Centre for Blood Research, British Columbia, V6T 1Z3, Canada.; Forschungszentrum Jülich, ZEA-3 Analytics, 52428 Jülich, Germany., Overall CM; University of British Columbia, Faculty of Dentistry, Centre for Blood Research, British Columbia, V6T 1Z3, Canada., Tartare-Deckert S; Côte d'Azur University, Inserm, C3M, Nice, France., Jacot W; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.; Translational Research Unit, ICM, Montpellier, France.; Department of Medical Oncology, ICM, Montpellier, France., Chardès T; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France., Guiu S; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.; Department of Medical Oncology, ICM, Montpellier, France., Roger P; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.; Department of Pathology, CHU Nîmes, Nîmes, France., Reinheckel T; Institute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany., Moali C; University of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.; University of Lyon, ENS de Lyon, INSERM US8, CNRS UMS3444, SFR Biosciences, F-69366 Lyon, France., Liaudet-Coopman E; IRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Source:	Theranostics [Theranostics] 2021 Apr 15; Vol. 11 (13), pp. 6173-6192. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1838-7640
DOI:	10.7150/thno.58254